Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with... | June 20, 2023
United States Wei Ky Aurinia Pharmaceuticals Meeting Of The European Renal Association Aurinia Pharmaceuticals Inc Annual Meeting
Source: marketscreener.com